论文部分内容阅读
Objective:To investigate the value of radionuclide whole-body bone imaging on monitoring chemotherapeutic effects for multiple myeloma(MM).Methods:Sixty patients were included.Twenty nine cases received CTD(thalidomide 100-200 mg/d;cyclophosphamide 200-300 mg/m2/d,1-4 days,every 4 weeks;and dexamethasone 20-40 mg/d,1-4 days,every 4 weeks);Thirty cases received VAD(vincristine 0.4 mg/d,1-4 days,every 4 weeks;adriamycin 10 mg/d,1-4 days,every 4 weeks;dexamethasone 40 mg/d,1-4 days,every 4 weeks).Radionuclide bone imagings were performed in all patients before chemotherapy,six months,twelve months and eighteen months after chemotherapy.The correlation of chemothera-peutic effects between CTD and VAD were analyzed.Results:One hundred and seventy nine bone lesions were visualized by bone scintigraphy before CTD treatment.Eighteen months after CTD chemotherapy,it was observed by bone scintigraphy that 39/179(21.78%) lesions disappeared,112/179(62.57%) improved,and 28/179(15.64%) had no change.One hundred and ninety one bone lesions were showed by bone imaging before VAD treatment,36/191(18.84%) lesions disappeared,eighteen months after chemotherapy,103/191(53.92%) improved,and 52/191(27.22%) had no change.The significant difference was observed in locations of MM induced bone lesions treated with CTD(H = 8.23,P < 0.05) and VAD(H = 11.18,P < 0.05).A significant chemotherapeutic sensitivity in detecting MM induced lesions in ribs was found compared with other bone lesions.The chemotherapeutic effect of CTD was statistically significant than that of VAD(U = 2.17,P < 0.05).Conclusion:Radionuclide whole-body bone imaging has great value in monitoring chemotherapeutic effects for MM.
Objective: To investigate the value of radionuclide whole-body bone imaging on monitoring chemotherapeutic effects for multiple myeloma (MM). Methods: Sixty patients were included. Twenty nine cases received CTD (thalidomide 100-200 mg / d; cyclophosphamide 200-300 mg / m2 / d, 1-4 days, every 4 weeks; and dexamethasone 20-40 mg / d, 1-4 days, every 4 weeks); Thirty cases received VAD (vincristine 0.4 mg / d, 1-4 days, every Adriamycin 10 mg / d, 1-4 days, every 4 weeks; dexamethasone 40 mg / d, 1-4 days, every 4 weeks). Radionuclide bone imagings were performed in all patients before chemotherapy, six months, and eighteen months after chemotherapy. correlation of chemothera-peutic effects between CTD and VAD were analyzed. Results: One hundred and seventy nine bone lesions were visualized by bone scintigraphy before CTD treatment. Eighteen months after CTD chemotherapy, it was observed by bone scintigraphy that 39/179 (21.78%) lesions disappeared, 112/179 (62.57%) improved, and 28/179 (15.64%) had no chang e.One hundred and ninety one bone lesions were showed by bone imaging before VAD treatment, 36/191 (18.84%) lesions disappeared, eighteen months after chemotherapy, 103/191 (53.92%) improved, and 52/191 (27.22%) had no change.The significant difference was observed in locations of MM induced bone lesions treated with CTD (H = 8.23, P <0.05) and VAD (H = 11.18, P <0.05) ribs was found compared with other bone lesions. The chemotherapeutic effect of CTD was quite significant than that of VAD (U = 2.17, P <0.05) .Conclusion: Radionuclide whole-body bone imaging has great value in monitoring chemotherapeutic effects for MM.